ZAKL FARMACEUTYCZNE POLPHARMA SA has a total of 17 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are MABWELL SHANGHAI BIOSCIENCE CO LTD, EUCLISES PHARMACEUTICALS INC and LUNAN NEW TIME BIO TECH CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 10 | |
#2 | United States | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | EAPO (Eurasian Patent Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Organic chemistry methods | |
#5 | Peptides | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Skoczen Przemyslaw | 8 |
#2 | Szulc Marcin | 6 |
#3 | Oracz Monika | 5 |
#4 | Majewski Arkadiusz | 4 |
#5 | Podwysocka Dominika | 4 |
#6 | Garczarek Piotr | 3 |
#7 | Cichocki Marek | 3 |
#8 | Drozd Aleksandra | 3 |
#9 | Zien Piotr Marcin | 3 |
#10 | Wisniewska Kornelia Bogumila | 3 |
Publication | Filing date | Title |
---|---|---|
EP3771465A1 | Pharmaceutical composition comprising dabigatran etexilate | |
WO2018091729A2 | Aqueous pharmaceutical formulations | |
WO2018002036A1 | Recombinant production of monoclonal antibodies | |
EP3407873A1 | Process for preparation of a granulate comprising dimethyl fumarate | |
EP3397247A1 | Process for preparation of an enteric coated granulate comprising dimethyl fumarate | |
EP3339292A1 | Cocrystals of apremilast | |
EP3390360A1 | Process for the preparation of a pharmaceutical agent | |
EP3455209A1 | Crystalline forms of apremilast | |
EP3228619A1 | Process for the preparation of apixaban |